Small molecule inhibition of RNA binding proteins in haematologic cancer
- PMID: 38329136
- PMCID: PMC10857685
- DOI: 10.1080/15476286.2024.2303558
Small molecule inhibition of RNA binding proteins in haematologic cancer
Abstract
In recent years, advances in biomedicine have revealed an important role for post-transcriptional mechanisms of gene expression regulation in pathologic conditions. In cancer in general and leukaemia specifically, RNA binding proteins have emerged as important regulator of RNA homoeostasis that are often dysregulated in the disease state. Having established the importance of these pathogenetic mechanisms, there have been a number of efforts to target RNA binding proteins using oligonucleotide-based strategies, as well as with small organic molecules. The field is at an exciting inflection point with the convergence of biomedical knowledge, small molecule screening strategies and improved chemical methods for synthesis and construction of sophisticated small molecules. Here, we review the mechanisms of post-transcriptional gene regulation, specifically in leukaemia, current small-molecule based efforts to target RNA binding proteins, and future prospects.
Keywords: Acute leukaemia; RNA binding proteins; RNA splicing; drug discovery; post-transcriptional gene regulation.
Conflict of interest statement
D.S.R. serves on advisory boards and has consulted for AbbVie, Inc., a pharmaceutical company that markets drugs for hematologic malignancies. The other authors declare no potential competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical